We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) closed at $2.36 in the latest trading session, marking a +1.29% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.03%. On the other hand, the Dow registered a loss of 0.11%, and the technology-centric Nasdaq increased by 0.13%.
Coming into today, shares of the company had lost 6.43% in the past month. In that same time, the Medical sector gained 1.25%, while the S&P 500 gained 0.6%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$0.15, marking a 44.44% rise compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.18 per share and a revenue of $8.77 million, demonstrating changes of +82.86% and 0%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Humacyte, Inc. holds a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know
Humacyte, Inc. (HUMA - Free Report) closed at $2.36 in the latest trading session, marking a +1.29% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.03%. On the other hand, the Dow registered a loss of 0.11%, and the technology-centric Nasdaq increased by 0.13%.
Coming into today, shares of the company had lost 6.43% in the past month. In that same time, the Medical sector gained 1.25%, while the S&P 500 gained 0.6%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$0.15, marking a 44.44% rise compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.18 per share and a revenue of $8.77 million, demonstrating changes of +82.86% and 0%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Humacyte, Inc. holds a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.